Aspen announces contract manufacturing agreement to initiate local production of Human Insulin for Novo Nordisk at its Gqeberha based sterile manufacturing facility Durban, South Africa – Aspen is pleased to announce further details on one of the contract manufacturing agreements mentioned in its recent announcement of financial results for the year ended 30 June 2023… Continue reading Aspen announces contract manufacturing agreement to initiate local production of Human Insulin for Novo Nordisk at its Gqeberha based sterile manufacturing facility
Aspen will be in a closed period from 1 January 2025 until the publication of the Interim Results on the JSE SENS platform on 3 March 2025.
